<DOC>
	<DOC>NCT01071018</DOC>
	<brief_summary>This study is designed to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MK2206 when administered with Every Other Day (QOD) and Once Weekly (QW) dosing schedules.</brief_summary>
	<brief_title>A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)</brief_title>
	<detailed_description />
	<criteria>Patient must have confirmed locally advanced or metastatic solid tumors that have failed to respond to standard therapy, have gotten worse or have come back after existing therapy Has adequate organ function Is ECOG Performance Scale 01 Has a negative urine pregnancy test if patient is female Is able to swallow capsules and has no surgical or bodily condition that will prevent the patient from swallowing and absorbing oral medications on an ongoing basis Patient has had chemotherapy, radiotherapy, biological therapy or surgery within 4 weeks of starting the study and has not recovered from adverse events caused by the treatment Is currently participating or has participated in a study with an investigational compound or device within 28 days Has a primary central nervous system tumor Has a history or current evidence of heart disease, slow heart rate or untreated high blood pressure Is a known diabetic who is taking insulin or oral antidiabetic therapy Is pregnant or breastfeeding or planning to become pregnant during the study Is positive HIV antibody, HBs antigen or HCV antibody</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>locally advanced or metastatic solid tumors</keyword>
</DOC>